Abalos Therapeutics raises €12.0M Series A round
15 October 2019· Düsseldorf, Germany· health, oncology, biotech, b2b, deep_hardware
The funding will be used to establish operations and leadership and to advance the company's arenavirus-based lead candidates towards clinical testing using its proprietary Fast Evolution platform.
Investors
LeadBoehringer Ingelheim Venture Fund
Also participating
High-Tech GründerfondsNRW.BankGründerfonds Ruhr
About Abalos Therapeutics
Stage
Series A
Headquarters
Düsseldorf, Germany
Founded
2019
Team Size
21–50
Sectors
healthoncologybiotechb2bdeep_hardware